Trial site
Lille
Lille, 59037, FranceNot linked to an institution yet
- 13running trials
- 10closed trials
The trials here
What the 23 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 25 trials
- Phase 1/22 trials
- Phase 42 trials
- Phase 2/31 trial
- Status
- Active, not recruiting9 trials
- Completed8 trials
- Recruiting4 trials
- Terminated2 trials
- Lead sponsor
- Novartis Pharmaceuticals23 trials
Running trials
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
NCT06704269· Phase 1/2· Novartis Pharmaceuticals· Source
Recruiting
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
NCT06514534· Phase 2· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256· Phase 2· Novartis Pharmaceuticals· Source
Active, not recruiting
Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation
NCT06444087· Novartis Pharmaceuticals· Source
Active, not recruiting
Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France
NCT06157086· Novartis Pharmaceuticals· Source
Recruiting
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
NCT05948943· Phase 2/3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
NCT04925479· Phase 1/2· Novartis Pharmaceuticals· Source
Active, not recruiting
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT04747613· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
NCT02962414· Phase 3· Novartis Pharmaceuticals· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment of Second-line Polycythemia Vera in France
NCT07839858· Novartis Pharmaceuticals· Source
Completed
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
NCT05562934· Phase 2· Novartis Pharmaceuticals· Source
Completed
Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
NCT05192941· Phase 4· Novartis Pharmaceuticals· Source
Completed
Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome
NCT04541589· Phase 2· Novartis Pharmaceuticals· Source
Terminated
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
NCT04266301· Phase 3· Novartis Pharmaceuticals· Source
Completed
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
NCT04023552· Phase 3· Novartis Pharmaceuticals· Source
Completed
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
NCT03056755· Phase 2· Novartis Pharmaceuticals· Source
Terminated
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
NCT02967692· Phase 3· Novartis Pharmaceuticals· Source
Completed
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
NCT01828099· Phase 3· Novartis Pharmaceuticals· Source
Completed
Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
NCT01742299· Phase 4· Novartis Pharmaceuticals· Source
Report an error